Research

Energy balance

There is a lack of studies comparing adverse events across different populations for glucagon-like peptide-1 receptor agonists.

Further research is needed to assess the safety of glucagon-like peptide-1 receptor agonists across diverse populations.

StrongRefutesmedium confidence
but there is a lack of studies comparing adverse events across different populations.
Christoffer Storm Baden et al. · Adverse Drug Reaction Bulletin · 2023

Why this rating

The review synthesizes existing literature to identify research gaps.

Source

Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: a scoping review

Christoffer Storm Baden et al. · Adverse Drug Reaction Bulletin · 2023

DOI 10.1097/fad.0000000000000067

reviewCited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →